

# Synthetic biodegradable polymers as drug delivery systems for bone morphogenetic proteins

N. Saito<sup>a,\*</sup>, N. Murakami<sup>b</sup>, J. Takahashi<sup>b</sup>, H. Horiuchi<sup>b</sup>, H. Ota<sup>b</sup>, H. Kato<sup>b</sup>, T. Okada<sup>c</sup>, K. Nozaki<sup>d</sup>, K. Takaoka<sup>e</sup>

*<sup>a</sup>Department of Physical Therapy, Shinshu University School of Health Sciences, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan*

*<sup>b</sup>Department of Orthopaedic Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan*

*<sup>c</sup>Research Institute, Taki Chemical Co., Ltd., 64-1 Nishiwaki, Befucho, Kakogawa, Hyogo 675-0125, Japan*

*<sup>d</sup>Applied Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan*

*<sup>e</sup>Department of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, 1-5-7 Asahimachi, Abeno-ku, Osaka 545-0051, Japan*

\*Corresponding author. Tel.: +81 263 37 2409. Fax: +81 263 35 8844.

*E-mail address:* [saitoko@hsp.md.shinshu-u.ac.jp](mailto:saitoko@hsp.md.shinshu-u.ac.jp) (N. Saito)

*Keywords:* Bone formation; Bone repair; Fracture; Bone defect; Recombinant human bone morphogenetic protein-2; Tissue engineering

## Abstract

Bone morphogenetic proteins (BMP) induce bone formation *in vivo*, and clinical application in repair of bone fractures and defects is expected. However, appropriate systems to deliver BMP for clinical use need to be developed. We synthesized a new synthetic biodegradable polymer, poly-D,L-lactic acid-para-dioxanon-polyethylene glycol block copolymer (PLA-DX-PEG), to serve as a biocompatible, biodegradable polymer for recombinant human (rh) BMP-2 delivery systems. In animal experiments new bone was efficiently formed and a large bone defect was repaired using PLA-DX-PEG/rhBMP-2 composites. In addition, this new polymer could be used as an injectable delivery system for rhBMP-2. The rhBMP-2/PLA-DX-PEG composites also could be combined with other materials such as hydroxyapatite or titanium. This new synthetic polymer might be used for rhBMP-2 delivery in various clinical situations involving repair of bone, leading to great changes in orthopedic treatment.

## Contents

1. Introduction
2. Bone morphogenetic proteins (BMP) and delivery systems
  - 2.1. BMP
  - 2.2. Delivery systems for BMP
  - 2.3. Synthetic polymers for BMP delivery system
3. Development of new synthetic biodegradable polymers for rhBMP-2 delivery
  - 3.1. Poly-D,L-lactic acid-polyethylene glycol block copolymer (PLA-PEG)
  - 3.2. Poly-D,L-lactic acid-para-dioxanone-polyethylene glycol block copolymer (PLA-DX-PEG)
4. Repair of bone tissues using rhBMP-2 and new synthetic polymers
  - 4.1. Repair of bone defect using composites of rhBMP-2 and synthetic polymers
  - 4.2. Injectable polymeric delivery systems for rhBMP-2
  - 4.3. Combination of the rhBMP-2/polymer composites with other materials
  - 4.4. Development of a new artificial joint that restores a bone defect
5. Conclusions

## **1. Introduction**

The regeneration potential of human bone appears to be limited, given that repair of large bone defects such as those associated with comminuted fractures or bone tumor resection usually remain unrepaired [1]. Such cases have been treated routinely with autogeneic or allogeneic bone grafting. Major problems associated with autogeneic grafting include limited anatomic sources of donor bone and risk of morbidity from the additional surgery for procurement of the graft. In allogeneic bone grafting, major concerns are potential risks of transmission of disease, immunologic reaction of the host, poor osteogenic capacity of the transplanted bone, and high costs associated with a bone banking system [2-4]. Current examination of alternatives to grafting techniques suggests three possible new approaches to inducing new bone formation: implantation of certain cytokines such as bone morphogenetic proteins (BMP) in combination with appropriate delivery systems at the target site [5-7]; transduction of genes encoding cytokines with osteogenic capacity into cells at repair sites [8,9]; and transplantation of cultured osteogenic cells derived from host bone marrow [10-13]. In our estimation, the second approach represents the next major advance, while the third requires considerable additional resources and time to procure and culture cells. The first strategy appears to show the most practical promise for the near future. Appropriate delivery systems are essential to this technique. In this review, we outline development of new delivery systems for BMP and preclinical animal experiments concerning bone tissue regeneration that suggest clinical applications.

## **2. Bone morphogenetic proteins (BMP) and delivery systems**

### **2.1. BMP**

BMP induce new bone formation by directing mesenchymal stem cells toward chondroblastic and osteoblastic differentiation, and causing them to proliferate *in vivo*. BMP expression has been confirmed to occur at the initial stage of the fracture healing process, and to participate in a cascade regulating bone repair processes. Also, new bone can be induced to form heterotopically, such as when the BMP are implanted in muscle in animal models using appropriate delivery systems. These observations suggest that BMP could be applied clinically to promotion of repair of bone.

BMP first was characterized in 1965 by Urist as a biologically active molecule inducing new ectopic bone formation from decalcified bone matrix *in vivo* [14]. A cDNA encoding BMP was cloned by Wozney in 1988, and BMP was found to be a dimeric protein with a molecular weight of about 32 000 [15-17]. An important common feature of the BMP molecules is the position of cysteine residues in relation to the carboxyl terminus. The positions of these seven cysteine residues are the same as those in transforming growth factor (TGF)- $\beta$ , indicating that BMP molecules are members of the TGF- $\beta$  superfamily [18]. Today, the BMP family consists of about 15 BMP [19].

BMP include bone formation during embryogenesis, growth, and adulthood. In fracture healing, osteoprogenitor cells can respond to BMP and differentiate into osteoblasts. BMP bind to their receptors on progenitor cells, initiating signal transduction according to the following sequence. BMP molecules bind to a type IA or IB BMP receptor (BMPR-I) and to a type II BMP receptor (BMPR-II) to form a heterotetramer. These receptors are of the serine/threonine kinase type. As a result of BMP binding, BMPR-II phosphorylate the glycine/serine-rich domain of BMPR-I. BMPR-I then phosphorylate the C-terminal domain of Smads 1, 5, and 8. [Smads is a term identifying homologues of "Mothers against decapentaplegic" (Mad) and the related genes, Sma.] Smad 6 blocks the

phosphorylation cascade by binding to BMPR-I. Following phosphorylation, Smads bind to Smad 4 and translocate to the nucleus. On the other hand, when Smads bind to Smad 6 the signal is terminated. Once inside the osteoblast nucleus, Smads initiate and activate Smad target gene transcription [20-22].

Among members of the BMP family, BMP-2, -4, and -7 possess a strong ability to induce bone formation. These BMP molecules have been synthesized successfully by DNA recombination techniques; the protein products (rBMP) have been shown to possess the bone-inducing effect of BMP [23,24]. Thus, human-type BMP (rhBMP) have become available for potential medical use. A number of preclinical studies have assessed the efficacy of rhBMP in healing of bone defects and acceleration of fracture healing.

## 2.2. Delivery systems for BMP

New bone formation *in vivo* cannot be obtained simply by injecting aqueous BMP solutions into the area where bone is needed. Delivery systems that retain BMP and release it slowly, as well as serving as scaffolding for new bone formation, are essential. A delivery system also must be biocompatible and biodegradable; lack immunogenicity, toxicity, and carcinogenicity; permit the biologic activity of BMP; be easily handled; be sterilizable; and be inexpensive to produce commercially. A large number of materials that satisfy these conditions have been considered as BMP delivery systems and tested in animals.

One of the first candidate materials was demineralized bone matrix (DBM), from which BMP were originally isolated [14,25]. Osteoconductive delivery systems have included collagenous materials, such as type I collagen (as sponges, gels, or fibrils) [19,26-30], and type IV collagen [31,32]; inorganic ceramic materials, such as hydroxyapatite (HA) (as a powder, granules, or

blocks) [33,34], tricalcium phosphate (TCP) [35], glass ceramic, and other inorganic materials; cartilage- or bone-derived materials, such as coral, chitin, and bone mineral; and composites of different types of these materials [20]. BMP have also been used in combination with titanium and other metal alloys [36].

Among these candidates the most effective material is type I collagen, which now is considered the “gold standard.” Type I collagen, a biologically occurring polymer, is a major component of bone and a suitable scaffold. In addition, collagen is degraded and absorbed *in vivo*, allowing its disappearance after new bone is formed. Since this collagen was extracted from tendons and skin of pigs and cattle, an atelocollagen was developed from these sources largely eliminating antigenicity. In animal tests, many excellent results have been obtained using this collagen with BMP. This atelocollagen delivery system also is used for clinical trials of BMP but some antigenicity remains, posing a degree of risk of immunologic reaction when used repetitively or in large amounts. Furthermore, a potential risk exists for transmission of infectious disease [37-39]. Finally, biodegradability and other properties are difficult to adjust. To avoid these problems, synthetic degradable polymers have been examined as possible BMP delivery systems.

### 2.3. Synthetic polymers for BMP delivery system

Synthetic biodegradable polymers pose no danger of immunogenicity or possibility of disease transmission. In addition, characteristics such as strength, degradability, and adhesiveness can be altered to facilitate clinical use.

Biodegradable polymers with high biocompatibility originated in the development of suture materials for surgery. These materials must be strong immediately after the operation when the tissue is sutured *in vivo*, but after the wound has healed, they ideally should degrade and be absorbed.

For this purpose, many biodegradable polymeric suture materials with high biocompatibility have been developed, and large-scale screening tests were carried out. As a result, several kinds of synthetic polymeric suture material are now in clinical use. These include poly- $\alpha$ -hydroxy acids such as polylactic acid (PLA), polyglycolic acid (PGA), and their copolymers (PLAGA). Their favorable characteristics as suture materials has prompted researchers to test their suitability as carriers for BMP.

BMP have been tested with a variety of biodegradable polymers including PLA, PGA, and PLAGA, and other polymers such as polyethylene glycol, poly- $\epsilon$ -caprolactone, and polyphosphazetes [40-46]. However, none has proven equal to collagen [47,48]. We therefore sought to develop new synthetic biodegradable polymers that would prove superior to collagen as BMP delivery system [49-52].

### **3. Development of new synthetic biodegradable polymers for rhBMP-2 delivery**

#### **3.1. Poly-D,L-lactic acid-polyethylene glycol block copolymer (PLA-PEG)**

Among rhBMP we tested rhBMP-2, which has been considered to possess greatest osteoinductive activity. First we tested biodegradable polymers for rhBMP-2 delivery that exhibited plasticity at room temperature. We synthesized PLA-PEG block copolymers of various molecular sizes with various PLA/PEG ratios (Fig. 1A) [53,54]. Results were assessed in vivo by mixing each polymer with rhBMP-2 and implanting the mixture into the back muscles of mice for 3 weeks to determine its capacity to induce ectopic bone formation. The results showed superiority of a PLA-PEG block copolymer with a total molecular weight of approximately 9500 and a PLA/PEG molar ratio of approximately 3:2. Although this polymer worked

well as a delivery system for rhBMP-2 and new ectopic bone was induced consistently, degradation of this polymer was somewhat slow; the material remained at the center of the rhBMP-2-induced ossicles.

### 3.2 Poly-D,L-lactic acid-para-dioxanone-polyethylene glycol block copolymer (PLA-DX-PEG)

To optimize degradation of the polymer used to deliver rhBMP-2, para-dioxanone molecules were randomly inserted into the PLA segments of the PLA-PEG polymer without changing the total molecular weight [55]. This PLA-DX-PEG block copolymer represents a novel material (Fig. 1B). Use of this new polymer as a delivery system for rhBMP-2 resulted in complete replacement of the implants by new bone with no visible remnants of the polymer, presumably reflecting a favorable degradation rate. *In vivo* comparison showed that the rhBMP-2/PLA-DX-PEG composite implants could induce new bone formation more effectively than a PLA-PEG/rhBMP-2 composite.

PLA-DX-PEG consists of a copolymer of polylactic acid and para-dioxanone and a homopolymer of polyethylene glycol. Individually, these polymers already have been used clinically as suture materials, screws, and delivery systems for other drugs. Therefore, PLA-DX-PEG is anticipated to be safe for clinical use as well. Nevertheless, further tests in large animals or primates are essential before this bone-inducing implant can be studied in a clinical setting. At room temperature, PLA-DX-PEG with molecular weight of 9500 is a firm gel that is easy to manipulate (Fig. 2). We tested whether this novel polymer could act as an effective rhBMP-2 delivery system.

The PLA-DX-PEG polymer mass was dissolved in organic solvent (acetone) and mixed with rhBMP-2 solution. After agitation, acetone was removed by evaporation with a centrifuge evaporator to return the polymer to its native state (Fig. 3). Male ddy mice (5 weeks old) were anesthetized with diethyl

ether, and test implants were aseptically placed into the left dorsal muscle pouches (one per animal). Three weeks after surgery the implants were harvested together with surrounding tissues. Soft X-ray radiographs and histologic examination of ectopic new bone showed mature trabecular bone and hematopoietic bone marrow (Fig. 4). No evidence of inflammatory or foreign-body reaction from the host could be found in tissues adjacent to the new bone.

We compared the PLA-DX-PEG polymer and collagen as rhBMP-2 delivery systems. For a positive control implant, an aliquot of rhBMP-2 solution was absorbed by a type I collagen sponge disc, lyophilized, and compressed to form an implant of the same volume as the PLA-DX-PEG implant. As a result, implants containing more than 0.5  $\mu\text{g}$  of rhBMP-2 showed bone formation in both groups. Therefore, in terms of ability to elicit new bone formation by rhBMP-2, the PLA-DX-PEG delivery system was equal to the collagen system. Amounts of calcium in the new bones induced in the PLA-DX-PEG and the collagen delivery system groups with 1  $\mu\text{g}$  or 10  $\mu\text{g}$  of rhBMP-2 were quantified. The mean calcium content in ossicles from the PLA-DX-PEG group was significantly higher than in those from the collagen group at both doses (Fig. 5). Therefore, this polymeric delivery system may permit reduction of the effective dose of rhBMP-2 for clinical use compared to doses used with collagen.

#### **4. Repair of bone tissues using rhBMP-2 and new synthetic polymers**

##### **4.1. Repair of bone defect using composites of rhBMP-2 and synthetic polymers**

Use of rhBMP-2 in combination with a delivery system material ideally forms new bone of the same shape as that of the original bone.

Development of synthetic biodegradable polymers is believed to permit control of the size and shape of newly formed bone if an appropriate delivery system is used. For this purpose the hard gel type of PLA-DX-PEG is suitable [55].

To test whether this novel polymer functions appropriately in large bone defects *in vivo*, we implanted rhBMP-2/PLA-DX-PEG composites in rat iliac bone defects 4 mm in diameters, which is considered a critical size for informative testing. We examined these defects using radiographic and histologic methods. The bone defect was repaired in a manner showing rhBMP-2 dose dependence and time dependence. Histologic analysis of the specimens revealed that defects treated with 10  $\mu$ g of rhBMP-2 were filled with dense trabecular bone with no evidence of polymer remnants at 4 weeks postoperatively. At the host-defect interface, new bone had formed adjacent to the host bone (Fig. 6). These results suggest that rhBMP-2 in the PLA-DX-PEG polymer delivery system should be suitable for eliciting bone formation and healing in large bone defects.

#### 4.2. Injectable polymeric delivery systems for rhBMP-2

Injectable delivery systems for rhBMP-2 could provide a less invasive method for repair of bone defects, avoiding extensive invasive surgery [56]. Clinical indications might include fresh fractures, nonunion, or delayed union of bone causing serious difficulty in fracture treatment, as well as large defects often associated with bone tumor resection. As far as we know, no such delivery system has been developed or reported.

The new synthetic biodegradable PLA-DX-PEG polymers feature an exquisite temperature-dependent liquid-semisolid transition and work well as an injectable rhBMP-2 delivery system. The thermosensitive property of the rhBMP-2/PLA-DX-PEG composite permits percutaneous injection after heating. Fluidity of the composite decreases as it cools to body temperature,

and the resultant semisolid form provides a scaffold for bone formation as it gradually releases rhBMP-2 into its immediate surroundings.

The rhBMP-2 molecule is a heat-stable protein [57]. For example, biologic activity of rhBMP-2 was unchanged after heating to 60°C for 30 min. Considering the heat-stable character of rhBMP-2, PLA-DX-PEG with molecular weight of 6400 could be a suitable system for injectable delivery of rhBMP-2. Together with rhBMP-2, this polymer heated to 60°C could be injected as a liquid and then turn to a semisolid form in vivo at 37°C. The properties of the polymer would allow retention of BMP for a period of time sufficient to elicit new bone formation while serving as a scaffold for further bone growth. Eventually, it would be completely replaced by new bone, avoiding surgery for removal since the polymer is biodegradable (Fig. 7A). To further demonstrate the efficacy of this polymer, 25 mg of PLA-DX-PEG mixed with 10 µg of rhBMP-2 was heated at 60°C for 5 min and injected using a 14-gauge needle into muscle overlying the surface of the murine femur. Three weeks after injection, new bone was found at the injection site, and was attached to the surface of the femur (Fig. 7B). This new type of injectable osteoinductive material should allow less invasive surgery involving restoration or repair of bone.

We also tested this injection technique in spinal fusion [58]. The rhBMP-2/PLA-DX-PEG composites were injected into the anterior longitudinal ligaments of the canine spine. Six weeks later, new bone had formed, bridging between the vertebrae anteriorly (Fig. 8). If a pneumoscopic technique were used jointly, anterior spinal fusion might be accomplished by a less invasive approach.

#### 4.3. Combination of the rhBMP-2/polymer composites with other materials

The hydrophilic nature of the PLA-DX-PEG polymer causes it to swell on contact with water. This physical property provides an additional

advantage for use of the polymer in combination with porous materials. When a solid implant with pores filled with the rhBMP-2/PLA-DX-PEG composite is implanted, the composite will swell, extruding itself from the pores to form a layer of composite.

To test this property, a combination of the rhBMP-2/PLA-DX-PEG composite with porous hydroxyapatite (HA) was used [54]. The rhBMP-2/PLA-DX-PEG composite was placed in the pores of an HA block, which then was inserted into the back muscle of mice. Over 3 weeks, new bone had formed to surround the HA. Histologic examination showed new bone formation within the pores of the HA as well (Fig. 9).

Next, rhBMP-2 (120  $\mu$ g) was mixed with the polymer (120 mg) and impregnated into titanium fiber-mesh cylinders [59]. Three 5-mm cylinders were placed end-to-end to fill a 15-mm defect created in the humerus of adult rabbits and stabilized with an intramedullary rod. In controls, the titanium fiber-mesh cylinders contained the polymer but not rhBMP-2. Six weeks after implantation, new bone had formed on the surface of the implant and had bridged the defect. Defects treated with control implants were not repaired (Fig. 10). These results provide strong evidence that composite implants using rhBMP-2, synthetic degradable polymers, and compatible materials provide enhanced regenerative potential for the repair of a large bone defect. These techniques can repair bones whose function requires great strength, as a combination of rhBMP-2/PLA-DX-PEG composite with HA or titanium represents a mechanically durable osteoinductive material.

#### 4.4. Development of a new artificial joint that restores a bone defect

Total hip arthroplasty (THA) has become essentially the standard procedure for treatment of various hip lesions. However, one limitation of this operation has been eventual loosening of the prosthesis from periprosthetic bone loss. At revision surgery, various degrees of bone defect,

both in the proximal femur and the acetabulum, often are encountered; these present challenges for sufficiently solid fixation of a new prosthesis.

Alternative approaches aimed at overcoming this problem have included special design of the revision prosthesis and allo- or autogeneic bone grafting in combination with or without materials such as hydroxyapatite. If such bone loss can be repaired with use of rhBMP-2, revision surgery might be made more effective.

To address the problem of loosening of the prosthesis, we developed a new prosthesis combined with rhBMP-2/PLA-DX-PEG composite [60]. We tested efficacy of the rhBMP-2-containing prosthesis in reconstructing a bone defect in a canine model where the medial half of the proximal femur was resected to create a defect that was repaired with rhBMP-2/PLA-DX-PEG composite. Twelve weeks after implantation, the original bone defects in the rhBMP-2 treatment groups showed repair (Fig. 11). Thus, this type of hybrid prosthesis may represent a new modality for repair of bone defects or restoration of lost bone mass encountered in revision arthroplasty.

## **5. Conclusions**

A new delivery system using PLA-DX-PEG enabled creation of various osteoinductive materials that could be used to heal fractures and repair large bone defects. Importantly, this new rhBMP-2 delivery system was developed using synthetic biodegradable polymers, avoiding potential risks of disease transmission or immunogenicity associated with use of animal collagen or allogeneic bone grafts. Moreover, this system avoids problems of autogenous bone grafts such as limited supply of donor bone and the need for additional surgery to harvest the bone, with the risk of additional morbidity.

In summary, this new rhBMP-2 delivery system represents an innovative potential therapy that is safe, efficacious, and less invasive than current

approaches for repair of damaged bone. Further work will be necessary to determine whether the biocompatible and biodegradable properties exhibited by the PLA-DX-PEG polymers in these studies are replicated during the practical application of rhBMP-2 in patient care.

## **Acknowledgements**

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan, a Grant of Japan Rheumatism Foundation, a Grant from Hip Joint Foundation of Japan, a Grant from Japan Orthopaedics and Traumatology Foundation Inc., a Grant from NOVARTIS Foundation (Japan) for the Promotion of Science, and a Grant from TERUMO Life Science Foundation.

## Figure legends

Fig. 1. Structural formulas of poly-D,L-lactic acid-polyethylene glycol block copolymer (PLA-PEG) and poly-D,L-lactic acid-p-dioxanone-polyethylene glycol block copolymer (PLA-DX-PEG). Both are A-B-A type polymers.  $m$ ,  $n$ ,  $o$ ,  $p$ ,  $q$ : number of units.

Fig. 2. Appearance of PLA-DX-PEG (reprinted from [51], with permission from Marcel Dekker Inc.) requires copyright permission since we previously published in Tissue engineering and novel delivery systems [51]. At room temperature, PLA-DX-PEG with a molecular weight of 9500 is a firm gel, which can be shaped and is easy to manipulate.

Fig. 3. Methods for combining PLA-DX-PEG polymer with rhBMP-2. PLA-DX-PEG was dissolved in organic solvent, and rhBMP-2 solution was mixed in. Evaporation with a centrifuge evaporator removed the solvent, so an rhBMP-2/PLA-DX-PEG composite implant was obtained.

Fig. 4. Ectopic bone formation induced by the rhBMP-2/PLA-DX-PEG composite (reprinted from [55], with permission from Nature Publishing Group) requires copyright permission since we previously published in Nat. Biotechnol. [55]. The composite was placed in the back muscle of mouse, which was harvested after 3 weeks. Ectopic new bone showed mature bone trabeculae with hematopoietic bone marrow. A: Soft X-ray radiograph. B: Photomicrograph. Hematoxylin and eosin stain.

Fig. 5. Comparison of calcium content of new bone obtained using an PLA-DX-PEG system and a collagen system (reprinted from [55], with permission from Nature Publishing Group) requires copyright permission since we previously published in Nat. Biotechnol. [55]. The calcium content

of new bone obtained using the PLA-DX-PEG system was significantly higher than that obtained using the collagen system for both 1  $\mu$ g and 10  $\mu$ g of rhBMP-2.

Fig. 6. Repair of a bone defect using PLA-DX-PEG as a delivery system for rhBMP-2 (reprinted from [55], with permission from Nature Publishing Group) requires copyright permission since we previously published in Nat. Biotechnol. [55]. A cylindrical defect 4 mm in diameter was created in the ilium of rats, and was filled with rhBMP-2/PLA-DX-PEG composite. A: The defect was repaired with newly formed bone in a manner dependent on rhBMP-2 dose and on time. B: New bone with hematopoietic marrow and bony trabeculae was formed adjacent to the host bone (arrows). Hematoxylin and eosin stain.

Fig. 7. Injectable polymeric delivery system for rhBMP-2 (reprinted from [56], with permission from Elsevier) requires copyright permission since we previously published in Bone [56]. A: When heated to 60°C, the rhBMP-2/PLA-DX-PEG composite can be injected percutaneously, avoiding need for surgical implantation. Subsequently, implants become firm upon cooling to body temperature, resulting in semisolid polymeric implants *in vivo*. B: Soft x-ray radiograph of new orthotopic bone formed by injection of the rhBMP-2/PLA-DX-PEG composite in the muscle pouch on the abraded surface of the murine femur 3 weeks after injection.

Fig. 8. Spinal fusion by injection of the rhBMP-2/PLA-DX-PEG composite (reprinted from [58], with permission from Lippincott Williams & Wilkins) requires copyright permission since we previously published in J. Spinal Disord. [58]. PLA-DX-PEG with rhBMP-2 was injected into the anterior longitudinal ligament of the spine in dogs. New bone was formed on the anterior aspects of vertebrae after 6 weeks (3D-CT, arrow).

Fig. 9. Ectopic bone formation by hydroxyapatite (HA) with the rhBMP-2/PLA-DX-PEG (reprinted from [54], with permission from The Journal of Bone and Joint Surgery, Inc.) requires copyright permission since we previously published in *J. Bone Joint Surg. Am.* [54]. The rhBMP-2/PLA-DX-PEG composite was placed in the pores the HA block, which was inserted in the back muscle of mice. A: Soft X-ray radiograph showed the new bone surrounding HA at 3 weeks. B: Histologic examination also showed new bone within the pores of the HA.

Fig. 10. Repair of a bone defect with a titanium syringe implant with the rhBMP-2/PLA-DX-PEG composite (reprinted from [59], with permission from Wiley) requires copyright permission since we previously published in *J. Biomed. Mater. Res.* [59]. A bone defect of 1.5 cm was created in the humerus of rabbits, and three 5-mm implants were placed in it. These were stabilized with an intramedullary rod. A: While the bone defect was not repaired in control groups, the defect was restored in the 120  $\mu$ g rhBMP-2 group after 5 weeks. B: Histologic examination showed that new bone also had formed within the titanium mesh (Ti), and that new bone had formed adjacent to the host bone. Hematoxylin and eosin stain.

Fig. 11. Repair of a periprosthetic bone defect using PLA-DX-PEG/rhBMP-2 composite adherent to the prosthesis (reprinted from [60], with permission from Elsevier) requires copyright permission since we previously published in *Biomaterials* [60]. A: Twelve weeks after implantation, the implant with rhBMP-2/PLA-DX-PEG showed new bone formation at the defect site. In the control group without rhBMP-2, only a scant amount of new bone was seen at the cut ends of the defects, which were not repaired. B: By microscopic examination of sections in the rhBMP-2 treatment group, the new bone on the surface of implants showed normal

histology with hematopoietic marrow and bony trabeculae. New bone formation also was observed within the pores of the titanium mesh.

Hematoxylin and eosin stain.

## References

- [1] T.S. Einhorn, Enhancement of fracture-healing, *J. Bone Joint Surg. Am.* 77 (1995) 940-956.
- [2] S.M. Doppelt, W.W. Tomford, A.B. Lucas, H.J. Mankin, Operational and financial aspects of a hospital bone bank, *J. Bone Joint Surg. Am.* 63 (1981) 1472-1481.
- [3] T.I. Malinin, O.V. Martinez, M.D. Brown, Banking of massive osteoarticular and intercalary bone allografts: 12 years' experience, *Clin. Orthop.* 197 (1985) 44-57.
- [4] J.A. Memzek, S.P. Arnoczky, C.L. Swenson, Retroviral transmission by the transplantation of connective-tissue allografts, *J. Bone Joint Surg. Am.* 76 (1995) 1034-1041.
- [5] E. Canalis, Effect of growth factors on bone cell replication and differentiation, *Clin. Orthop.* 193 (1985) 246-263.
- [6] A.H. Reddi, Symbiosis of Biotechnology and biomaterials: application in tissue engineering of bone and cartilage, *J. Cell Biochem.* 56 (1994) 192-195.
- [7] U. Ripamonti, A.H. Reddi, Tissue engineering, morphogenesis, and regeneration of the periodontal tissues by bone morphogenetic proteins, *Crit. Rev. Oral Biol. Med.* 8 (1997) 154-163.
- [8] J. Fang, Y.Y. Zhu, E. Smiley, J. Bonadio, J.P. Rouleau, S.A. Goldstein, L.K. McCauley, B.L. Davidson, B.J. Roessler, Stimulation of new bone formation by direct transfer of osteogenic plasmid gene, *Proc. Natl. Acad. Sci. USA* 93 (1996) 5753-5758.
- [9] J. Bonadio, E. Smiley, P. Patil, S. Goldstein, Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration, *Nature Med.* 5 (1999) 753-759.
- [10] A.I. Caplan, Mesenchymal stem cells, *J. Orthop. Res.* 9 (1991) 641-650.
- [11] S.E. Haynesworth, J. Goshima, V.M. Goldberg, A.I. Caplan,

- Characterization of cells with osteogenic potential from human marrow, *Bone* 13 (1992) 81-88.
- [12] H. Ohgushi, Y. Dohi, T. Toshikawa, S. Tamai, S. Tabata, Y. Suwa, In vitro bone formation by rat marrow cell culture, *J. Biomed. Mat. Res* 32 (1996) 341-348.
- [13] S. Tamura, H. Kataoka, Y. Matsui, Y. Shionoya, K. Ohno, K.I. Michi, K. Takahashi, A. Yamaguchi, The effects of transplantation of osteoblastic cells with bone morphogenetic protein (BMP)/carrier complex on bone repair, *Bone* 29 (2001) 169-175.
- [14] M.R. Urist, Bone formation by autoinduction, *Science* 150 (1965) 893-899.
- [15] J.M. Wozney, V. Rosen, A.J. Celeste, L.M. Mitsock, M.J. Whitters, R.W. Kriz, R.M. Hewick, E.A. Wang, Novel regulators of bone formation: molecular clones and activities, *Science* 242 (1988) 1528-1534.
- [16] K. Takaoka, H. Yoshikawa, J. Hashimoto, S. Miyamoto, K. Masuhara, H. Nakahara, M. Matsui, K. Ono, Purification and characterization of a bone-inducing protein from a murine osteosarcoma (Dunn type), *Clin. Orthop.* 292 (1993) 122-129.
- [17] K. Takaoka, H. Yoshikawa, J. Hashimoto, . Masuhara, S. Miyamoto, S. Suzuki, K. Ono, M. Matsui, S. Oikawa, N. Tsuruoka, Y. Tawaragi, C. Inuzuka, T. Katayama, M. Sugiyama, M. Tsujimoto, T. Nakanishi, H. Nakazatio, Gene cloning and expression of a bone morphogenetic protein derived from a murine osteosarcoma, *Clin. Orthop.* 294 (1994) 344-352.
- [18] A.J. Celeste, J.A. Iannazzi, R.C. Taylor, R.M. Hewick, V. Rosen, E.A. Wang, J.M. Wozney, Identification of transforming growth factor  $\beta$  family members present in bone inductive protein purified from bovine bone, *Proc. Natl. Acad. Sci. USA* 87 (1990) 9843-9847.
- [19] M. Geiger, R.H. Li, W. Friess, Collagen sponges for bone regeneration with rhBMP-2, *Adv. Drug Deliv. Rev.* 55 (2003) 1613-1629.

- [20] C.A. Kirker-Head, Potential applications and delivery strategies for bone morphogenetic proteins, *Adv. Drug Deliver. Rev.* 43 (2000) 65-92.
- [21] T. Sakou, Bone morphogenetic proteins: from basic studies to clinical approaches, *Bone* 22 (1998) 591-603.
- [22] J.M. Schmitt, K. Hwang, S.R. Winn, J.O. Hollinger, Bone morphogenetic proteins: an update on basic biology and clinical relevance, *J. Orthopaed. Res.* 17 (1999) 269-278.
- [23] E.A. Wang, V. Rosen, Recombinant human bone morphogenetic protein induces bone formation, *Proc. Natl. Acad. Sci. USA* 87 (1990) 2220-2224.
- [24] J.M. Wozney, The bone morphogenetic protein family and osteogenesis, *Mol. Reprod. Dev.* 32 (1992) 160-167.
- [25] T.K. Sampath, J.E. Coughlin, R.M. Whetstone, D. Banach, C. Corbett, R.J. Ridge, E. Ozkaynak, H. Oppermann and D.C. Rueger, Bovine osteogenic protein is composed of dimers of OP-1 and BMP2A, two members of the transforming growth factor beta superfamily, *J. Biol. Chem.* 265 (1990), 13198–13250.
- [26] K. Takaoka, M. Koezuka, H. Nakahara, Telopeptide-depleted bovine skin collagen as a carrier for bone morphogenetic protein, *J. Orthop. Res.* 9 (1991) 902-907.
- [27] S.D. Cook, M.W. Wolfe, S.L. Salkeld, D.C. Rueger, Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates, *J. Bone Joint Surg. Am.* 77 (1995) 734-750.
- [28] J.H. Schimandle, S.D. Boden, W.C. Hutton, Experimental spinal fusion with recombinant human bone morphogenetic protein-2, *Spine* 20 (1995) 1326-1337.
- [29] U. Ripamonti, M. Heliotis, D.C. Rueger, T.K. Sampath, Induction of cementogenesis by recombinant human osteogenic protein-1 (hOP-1/BMP-7) in the baboon (*Papio ursinus*), *Arch. Oral Biol.* 41 (1996) 121-126.

- [30] H. Itoh, S. Ebara, M. Kamimura, Y. Tateiwa, T. Kinoshita, Y. Yuzawa, K. Takaoka, Experimental spinal fusion with use of recombinant human bone morphogenetic protein 2, *Spine* 24 (1999) 1402-1405.
- [31] V.V. Viljanen, T.J. Gao, T.C. Lindholm, T.S. Lindholm, B. Kommonen, Xenogeneic moose (*Alces alces*) bone morphogenetic protein (mBMP)-induced repair of critical-size skull defects in sheep, *Int. J. Oral Maxillofac. Surg.* 25 (1996), 217–222.
- [32] T.J. Gao, T.S. Lindholm, B. Kommonen, P. Ragni, A. Paronzini, T.C. Lindholm, T. Jamsa, P. Jalovaara, Enhanced healing of segmental tibial defects in sheep by a composite bone substitute composed of tricalcium phosphate cylinder, bone morphogenetic protein, and Type IV collagen, *J. Biomed. Mater. Res.* 32 (1996), 505–512.
- [33] E. Tsuruga, H. Takita, H. Itoh, Y. Wakisaka, Y. Kuboki, Pore size of porous hydroxyapatite as the cell-substratum controls BMP-induced osteogenesis, *J. Biochem.* 121 (1997), 317–324.
- [34] J.A. Koempel, B.S. Patt, K. O’Grady, J. Wozney, D.M. Toriumi, The effect of recombinant human bone morphogenetic protein-2 on the integration of porous hydroxyapatite implants with bone, *J. Biomed. Mater. Res.* 41 (1998), 59–63.
- [35] D.D. Lee, A. Tofighi, M. Aiolova, P. Chakravarthy, A. Catalano, A. Majahad, D. Knaack, Alpha-BSM: a biomimetic bone substitute and drug delivery vehicle, *Clin. Orthop.* 367 (1999), S396–S405.
- [36] B.J. Cole, M.P. Bostrom, T.L. Pritchard, D.R. Sumner, E. Tomin, J.M. Lane, A.J. Weiland, Use of bone morphogenetic protein 2 on ectopic porous coated implants in the rat, *Clin. Orthop.* 345 (1997), 219–228.
- [37] F.H. Bach, J.A. Fishman, N. Daniels, J. Proimos, B. Anderson, C.B. Carpenter, L. Forrow, S.C. Robson, H.V. Fineberg, Uncertainty in xenotransplantation: individual benefit versus collective risk, *Nat. Med.* 4 (1998) 141-144.
- [38] D. Butler, M. Wadman, S. Lehrman, Q. Schiermeier, Last chance to stop

- and think on risks of xenotransplants, *Nature* 391 (1998) 320-324.
- [39] F. DeLustro, J. Dasch, J. Keefe, L. Ellingsworth, Immune responses to allogeneic and xenogeneic implants of collagen and collagen derivatives, *Clin. Orthop.* 260 (1990) 263-279.
- [40] J.O. Hollinger, G.C. Battistone, Biodegradable bone repair materials: synthetic polymers and ceramics, *Clin. Orthop.* 207 (1986) 290-305.
- [41] R. Kenley, L. Marden, T. Turek, L. Jin, E. Ron, J.O. Hollinger, Osseous regeneration in the rat calvarium using novel delivery system for recombinant human bone morphogenetic protein-2 (rhBMP-2), *J. Biomed. Mater. Res.* 28 (1994) 1139-1147.
- [42] S.C. Lee, M. Shea, M.A. Battle, K. Kozitza, E. Ron, T. Turek, R.G. Schaub, W.C. Hayes, Healing of large segmental defects in rat femurs is aided by rhBMP-2 in PLGA matrix, *J. Biomed. Mater. Res.* 28 (1994) 1149-1156.
- [43] M.C. Meikle, S. Papaioannou, T.J. Ratledge, P.M. Speight, S.R. Watt-Smith, P.A. Hill, J.J. Reynolds, Effect of poly DL-lactide-co-glycolide implants and xenogeneic bone matrix-derived growth factors on calvarial bone repair in the rabbit, *Biomaterials* 15 (1994) 513-521.
- [44] H.S. Sandhu, L.E.A. Kanim, J.M. Kabo, J.M. Toth, E.N. Zeegen, D. Liu, L.L. Seeger, E.G. Dawson, Evaluation of rhBMP-2 with an OPLA carrier in a canine posterolateral (transverse process) spinal fusion model, *Spine* 20 (1995) 2669-2682.
- [45] M. Bostrom, J.M. Lane, E. Tomin, M. Browne, W. Berberian, T. Turek, J. Smith, J. Wozney, T. Schildhauer, Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model, *Clin. Orthop.* 327 (1996) 272-282.
- [46] M. Mayer, J. Hollinger, E. Ron, J. Wozney, Maxillary alveolar cleft repair in dogs using recombinant human bone morphogenetic protein-2 and polymer carrier, *Plast. Reconstr. Surg.* 98 (1996) 247-259.
- [47] O.M. Bostman, Absorbable implants for the fixation of fracture, *J. Bone*



- Joint Surg. Am. 73 (1991) 148-153.
- [48] J.O. Hollinger, K. Leong, Poly( $\alpha$ -hydroxy acids): carriers for bone morphogenetic proteins, *Biomaterials* 17 (1996) 187-194.
- [49] K. Takaoka, N. Saito, S. Miyamoto, H. Yoshikawa, T. Okada, in: Y. Ikada, T. Okano (Eds.), *Bone-inducing implants: new synthetic absorbable poly-D,L-lactic acid-polyethylene glycol block copolymers as BMP-carriers*, *Tissue engineering for therapeutic use*, Vol. 3, Elsevier Science B.V., Amsterdam, 1999, pp. 141-151.
- [50] K. Takaoka, S. Miyamoto, N. Saito, T. Okada, in: D.L. Wise (Ed.), *New synthetic degradable polymers as carrier materials for BMP*, *Biomaterials engineering and devices: human applications*, Vol. 1, The Humana Press, New Jersey, 2000, pp. 239-249.
- [51] N. Saito, H. Horiuchi, N. Murakami, J. Takahashi, T. Okada, K. Nozaki, K. Takaoka, in: M.J. Yaszemski, D.J. Trantolo, K.U. Lewandrowski, V. Hasirci, D.E. Altobelli, D.L. Wise (Eds.), *New synthetic biodegradable polymers for bone morphogenetic protein delivery systems*, *Tissue engineering and novel delivery systems*, Marcel Dekker inc., New York, 2004, pp. 475-482.
- [52] N. Saito, K. Takaoka, *New synthetic biodegradable polymers as BMP carriers for bone tissue engineering*, *Biomaterials* 24 (2003) 2287-2293.
- [53] N. Saito, T. Okada, S. Toba, S. Miyamoto, K. Takaoka, *New synthetic absorbable polymers as BMP-carriers: plastic properties of poly-D,L-lactic acid-polyethylene glycol block copolymers*, *J. Biomed. Mater. Res.* 47 (1999) 104-110.
- [54] N. Saito, T. Okada, H. Horiuchi, N. Murakami, J. Takahashi, M. Nawata, H. Ota, S. Miyamoto, K. Nozaki, K. Takaoka, *Biodegradable poly-D,L-lactic acid-polyethylene glycol block copolymers as a BMP delivery system for inducing bone*, *J. Bone Joint Surg. Am.* 83 Suppl 1 (2001) 92-98.
- [55] N. Saito, T. Okada, H. Horiuchi, N. Murakami, J. Takahashi, M.

- Nawata, H. Ota, K. Nozaki, K. Takaoka, A biodegradable polymer as a cytokine delivery system for inducing bone formation, *Nat. Biotechnol.* 19 (2001) 332-335.
- [56] N. Saito, T. Okada, H. Horiuchi, H. Ota, J. Takahashi, N. Murakami, M. Nawata, S. Kojima, K. Nozaki, K. Takaoka, Local bone formation by injection of recombinant human bone morphogenetic protein-2 contained in polymer carriers, *Bone* 32 (2003) 381-386.
- [57] H. Izawa, Y. Hachiya, T. Kawai, K. Muramatsu, Y. Narita, N. Ban, H. Yishizawa, The effect of heat-treated human bone morphogenetic protein on clinical implantation, *Clin. Orthop.* 390 (2001) 252-258.
- [58] J. Takahashi, N. Saito, S. Ebara, T. Kinoshita, H. Itoh, T. Okada, K. Nozaki, K. Takaoka, Anterior thoracic spinal fusion in dogs by injection of recombinant human bone morphogenetic-2 and a synthetic polymer, *J. Spinal Disord.* 16 (2003) 137-143.
- [59] N. Murakami, N. Saito, H. Horiuchi, T. Okada, K. Nozaki, K. Takaoka, Repair of segmental defects in rabbit humeri with titanium fiber mesh cylinders containing recombinant human bone morphogenetic protein-2 (rhBMP-2) and a synthetic polymer, *J. Biomed. Mater. Res.* 62 (2002) 169-174.
- [60] N. Murakami, N. Saito, J. Takahashi, H. Ota, H. Horiuchi, M. Nawata, T. Okada, K. Nozaki, K. Takaoka, Repair of a proximal femoral bone defect in dogs using a porous surfaced prosthesis in combination with recombinant BMP-2 and a synthetic polymer carrier, *Biomaterials* 24 (2003) 2153-2159.

## PLA-PEG




## PLA-DX-PEG



**Fig. 1**




**Fig. 2**



**Fig. 3**




**A**




**B**


**Fig. 4**



**Fig. 5**





**A**




**B**


**Fig. 6**




**Fig. 7**



**Fig. 8**



**A**




**B**

**Fig. 9**

**A**


**Control**



**rhBMP-2  
120 mg**



**B**




**Fig. 10**



**Control**



**rhBMP-2  
PLA-DX-PEG**



**B**

**A**

**Fig. 11**